^
3d
New trial
|
EGFR expression
3d
Phase II/III Trial of SYS6010 plus Enlonstobart Injection ± Chemotherapy in Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ChiCTR2500112440)
P2/3, N=737, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
New P2/3 trial
|
PD-L1 (Programmed death ligand 1)
|
EGFR expression
|
cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • leucovorin calcium • Enshuxing (enlonstobart) • SYS6010
3d
New P1 trial
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 20 insertion • EGFR expression • EGFR L861Q • EGFR S768I • EGFR positive
3d
A phase Ib/II clinical trial on the safety and efficacy of sirolimus (albumin-bound) combined with different ADCs in patients with advanced solid tumors (ChiCTR2500111937)
P1, N=444, Not yet recruiting, Fudan University Shanghai Cancer Center; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
New P1 trial
|
EGFR (Epidermal growth factor receptor) • CD276 (CD276 Molecule) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
HER-2 negative • HER-2 expression • EGFR expression
|
sirolimus • trastuzumab envedotin (DP303c) • SYS6010 • sirolimus for injection (albumin-bound) (SRL-HSA)
3d
Antibody-Targeted Artificial T Cell and Natural Killer Cell Derived Vesicles for Cancer Immunotherapy. (PubMed, J Extracell Vesicles)
We targeted T and NK92 ACDVs to cancer cells possessing the xenoantigen, N-glycolyl neuraminic acid GM3 ganglioside, using the 14f7hT antibody or the tumour antigen, epidermal growth factor receptor, using the nimotuzumab antibody...14F7hT-conjugated NK92 ACDVs showed cytotoxic activity against chronic lymphocytic leukaemia biopsies. This research shows the potential for using antibody-conjugated, cytotoxic T and NK ACDVs as a feasible and effective approach for tumour-targeted immunotherapy.
Journal
|
EGFR (Epidermal growth factor receptor) • FASLG (Fas ligand) • GZMA (Granzyme A)
|
EGFR expression
|
TheraCIM (nimotuzumab)
4d
Primary Hepatic Hemangiosarcoma With Hemoperitoneum in a Dog: Clinical Course and Therapeutic Outcome. (PubMed, Case Rep Vet Med)
The multimodal therapeutic approach included one attempted VAC cycle (discontinued due to Grade 4 neutropenia), five cycles of single-agent doxorubicin, and subsequent administration of toceranib with dose reduction for anemia...Postmortem extended immunohistochemistry demonstrated heterogeneous receptor tyrosine kinase (RTK) expression: EGFR and VEGFR positivity, strong membranous HER2 labeling in approximately 60% of tumor cells, low KIT expression, and negative PDGFR. This case underscores the aggressive metastatic nature of primary hepatic hemangiosarcoma following rupture and highlights practical considerations for systemic therapy selection and adverse event monitoring in clinical practice.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
EGFR expression • KIT expression
|
doxorubicin hydrochloride
5d
Radiomics-based gradient boosting model on contrast-enhanced MRI for non-invasive prediction of epidermal growth factor receptor expression and therapeutic response to EGFR-targeted antibody-drug conjugates in high-grade glioma organoid models. (PubMed, J Transl Med)
EGF/EGFR expression is associated with immunosuppressive microenvironments and adverse outcomes in HGG. Radiomics may provide a non-invasive approach for estimating EGFR expression, although model performance requires external validation and EGFR-ADCs showed partial inhibitory activity within the tested range, though potency remains to be defined.These findings suggest a framework into radiogenomic stratification and targeted therapy in GBM.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • CD4 (CD4 Molecule)
|
EGFR expression • EGFR positive
|
temozolomide • sirolimus
6d
Profiling the Complexity of Resistance Factors in Cancer Cells Towards Berberine and Its Derivatives. (PubMed, Pharmaceuticals (Basel))
Berberine altered the microtubule cytoskeleton similarly to vincristine...Their relationship to berberine and its derivatives is novel. Berberine-type compounds may be new candidates against cancer; however, they may develop drug resistance.
Journal
|
EGFR (Epidermal growth factor receptor) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • WT1 (WT1 Transcription Factor)
|
EGFR expression
|
vincristine
6d
Harnessing Dual Power: Genistein-Loaded Pumpkisomes in Pullulan Microneedles for Potent Antioxidant and Anticancer Therapy Against Ehrlich Ascites Carcinoma and Breast Cancer Cells. (PubMed, Pharmaceutics)
Histological study revealed decreased mitotic activity and large tumor cells, with minimal systemic damage. GNS-PKs-pullulan microneedle system offers a hope for an innovative, potent, effective, and non-invasive strategy for breast cancer treatment with high antitumor efficacy.
Journal
|
EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
EGFR expression
7d
Exosomes displaying native EGF enhance doxorubicin's therapeutic efficacy and reduce cardiotoxicity. (PubMed, J Nanobiotechnology)
Our findings demonstrate that tumor-derived exosomes engineered with EGF on their surface enable targeted drug delivery to tumors with high EGFR expression. Although the exosomes modestly increase cell proliferation in vitro, the EGF-Exo-DOX formulation exhibits enhanced tumor accumulation relative to the heart, minimal cardiac uptake, and shows no tumorigenic effects in vivo. Compared to Lipo-DOX, a widely used clinical formulation of liposomal DOX in China, EGF-Exo-DOX demonstrates superior cellular uptake, greater induction of tumor cell apoptosis, and improved anti-tumor efficacy. These results highlight the potential of engineered exosomes as a targeted drug delivery platform for patients with EGFR-overexpressing tumors.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression
|
doxorubicin hydrochloride • pegylated liposomal doxorubicin
8d
Efficacy and safety of SMET12 in combination with toripalimab and chemotherapy in advanced non-small-cell lung cancer patients tested positive for EGFR protein who are treatment-naïve or harbor acquired resistance to standard therapy: a phase 2, multi-cohort clinical trial. (PubMed, Front Immunol)
The functional phenotype and differentiation pattern of peripheral blood T lymphocytes exert a critical impact on the therapeutic response to this triple therapy. https://www.clinicaltrials.gov/study/, identifier NCT06208033.
Clinical • P2 data • Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CD69 (CD69 Molecule)
|
EGFR mutation • EGFR expression • EGFR positive
|
Loqtorzi (toripalimab-tpzi)
12d
Association Between EGFR Expression in Non-Small Cell Lung Cancer and Dietary Legume Intake. (PubMed, Curr Drug Targets)
High legume intake correlates with improved prognosis and lower EGFR expression in NSCLC. Further large-scale prospective studies are needed to validate these associations and explore their clinical implications.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression • EGFR positive